LGD-4033 vs Noopept
Moderate Research vs Moderate Research
monitor Mechanism-based · 51% Both LGD-4033 and Noopept can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
LGD-4033 Noopept
Weight 338.25 Da 318.37 Da
Half-life ~24-36 hours ~30 minutes (oral), active metabolite cycloprolylglycine persists longer
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Dipeptide derivative (C17H22N2O4)
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Noopept
01 Enhanced memory formation and consolidation through upregulation of BDNF and NGF
02 Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
03 Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
04 Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
05 Anxiolytic properties observed at standard nootropic doses without sedation
06 Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Noopept
Headache (most common side effect, typically caused by insufficient choline intake -- co-supplementation with Alpha-GPC or CDP-Choline usually resolves this)
Irritability and restlessness, particularly at doses exceeding 30 mg/day
Insomnia if taken too late in the day
Mild gastrointestinal discomfort when taken on an empty stomach
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Known hypersensitivity to Noopept or related compounds
Severe hepatic impairment (metabolized by the liver)
Severe renal impairment
Pregnancy and breastfeeding (insufficient safety data)
Hypertension that is poorly controlled (due to potential mild pressor effects)
Research Evidence
LGD-4033 Noopept
Status Moderate Research Moderate Research
References 5 studies 4 studies
Latest 2018 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.